This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Journal of Hematology & Oncology Open Access 20 June 2018
-
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
Journal of Cancer Research and Clinical Oncology Open Access 23 May 2015
-
Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
Journal of Hematopathology Open Access 10 February 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–580.
Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312–314.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.
Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644–3654.
Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741–1744.
Kantarjian HM, Ottmann O, Cortes J, Wassmann B, Jones D, Hochhaus A et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). ASCO, Orlando 2005. p 195s.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
von Bubnoff, N., Gorantla, S., Kancha, R. et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19, 1670–1671 (2005). https://doi.org/10.1038/sj.leu.2403887
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403887
This article is cited by
-
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Journal of Hematology & Oncology (2018)
-
The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy
Leukemia (2015)
-
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
Journal of Cancer Research and Clinical Oncology (2015)
-
Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
Journal of Hematopathology (2009)
-
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
British Journal of Cancer (2006)